High-mobility group protein B1 derived mutant peptide mB Box-97 inhibits the formation of neutrophil extracellular traps
mB Box-97 is a promising dual acting therapeutic candidate for managing NET-mediated pathologies and resolving biofilm infections. Our results reveal that PKC is a viable target for NETosis inhibition independent of NET inducer and worthy of further study. These findings pave the way for a novel class of therapeutics aimed at controlling excessive NETosis, potentially offering new treatments for a range of inflammatory and immune-related diseases.
Authors
- Frank Robledo‐Avila (ORCID: https://orcid.org/0000-0001-5583-9194)
- Kunal R. More (ORCID: https://orcid.org/0000-0001-5152-5104)
- Steven D. Goodman (ORCID: https://orcid.org/0000-0002-3315-9320)
- Aishwarya Devaraj (ORCID: https://orcid.org/0000-0001-8129-7843)
- Santiago Partida‐Sánchez (ORCID: https://orcid.org/0000-0003-2996-9440)
- Lauren O. Bakaletz (ORCID: https://orcid.org/0000-0002-0017-1710)
Institutions
- Nationwide Children's Hospital (US)
- The Ohio State University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1565252
- Citations
- 3
- Primary Topic
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- National Institutes of Health
- National Institute on Deafness and Other Communication Disorders
- National Institute of Allergy and Infectious Diseases